Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Global Generics Guide 2nd Edition: Optimizing Geographical and Strategic Positioning in an Evolving Generics Landscape Datamonitor, Nov 2003, Pages: 366   Description     Table of Contents        Enquire before Buying    Send to a Friend   Introduction The global generics market is changing. A favorable environment in the US has lead to intense competition in commodity generics, and left players seeking alternative options to drive further growth. Meanwhile, regulatory reform in under penetrated EU generics markets is boosting generic usage, attracting attention from overseas players, and bringing with it its own set of challenges. Scope Benchmarking of leading generics players by 2002 sales, market share and financial position and by forecast ethical sales between 2003 and 2008 Analysis of portfolio management and geographic expansion strategies specific to US and EU based players Full profiles of 11 leading generics players - Alpharma, Andrx, Barr, Biovail, IVAX, Mylan, Ranbaxy, SICOR, Stada, Teva, Watson Report Highlights The global generics market is forecast strong growth between 2003 and 2008. In the US, patent expiries will be the key driver, with $84 billion worth of 2002 blockbusters being at risk of generic competition by 2008. Europe is expected to outperform the US in terms of rate of growth in generics sales, with increased generic usage the key driver. Despite the introduction of cost containment measures resulting in price cuts in mature generics markets such as the UK and Germany, the net benefit of regulatory reform and cost containment measures will be positive for the European generics industry, particularly in those markets where generic penetration is currently very low. In 2008, the best positioned generics companies will be those that have technology platforms enabling them to maintain margins in face of increased competition, and that have international manufacturing and distribution networks that allow them to profit from the growth potential in southern European markets. Reasons to Purchase Understand the drivers of growth in the major generics markets, and tailor your portfolio management strategy to maximize profit return Benchmark your strategy against key rivals in the generics sector Assess the impact of regulatory reform and increased generic penetration on the branded sector Customers who bought this item also bought Pharmavitae Generics - Teva Mylan: PharmaVitae Generics Profile Generics Series: Generics Trends in the Seven Major Markets and Beyond Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy Global Generics Guide: Capitalizing On an $82 Billion Opportunity Global Generics Industry Report Growth Strategies In Generics: Innovative And Aggressive Strategies And Their Impact On Branded Pharmaceuticals Global Generics Guide: Benchmarking the Key Players Teva Pharmaceutical Industries Generics Company Intelligence Report Generics: Global Industry Guide Watson: PharmaVitae Generics Profile Barr: PharmaVitae Generics Profile

		Top of page

All rights reserved. � Copyright 2009 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster